logo BDSP

Base documentaire


  1. Cost-effectiveness analysis of the conversion of patients with non-insulin-dependent diabetes mellitus from glipizide to glyburide and of the accompanying pharmacy follow-up clinic.

    Article - En anglais

    At the Department of Veterans'Affairs Outpatient Clinic in Columbus, Ohio, patients with non-insulin-dependent diabetes mellitus who were receiving glipizide therapy were converted to glyburide therapy over a 6-month period starting in mid-1993.

    A pharmacy follow-up clinic was instituted to help patients with problems associated with the transition.

    An initial analysis of the conversion indicated a savings of $65,000.00 to the Department of Veterans'Affairs (VA) based on the drug acquisition cost differential alone.

    The purpose of our study was to retrospectively evaluate the cost-effectiveness of the conversion and the pharmacy follow-up clinic from the perspective of the VA pharmacy department.

    Relevant costs and effectiveness (percentage of patients who achieved good glycemic control) were examined for three groups :

    • group I-patients who were treated with glipizide ;

    • group II-patients who were switched from glipizide to glyburide, accompanied by a pharmacy follow-up clinic ;

    • and group III-patients who were switched from glipizide to glyburide, with no follow-up clinic.

    Overall, group III had the lowest costs, and group II appeared to be the most effective.

    Cost-effectiveness analysis indicated that the conversion from glipizide to glyburide was cost-effective.

    Incremental analysis performed for the follow-up group over the no follow-up group showed that for every 1% of patients who achieved good glycemic control, the VA would spend $1.01 more for the follow-up group.

    Mots-clés Pascal : Glipizide, Glibenclamide, Chimiothérapie, Diabète non insulinodépendant, Traitement, Modification, Coût, Homme, Economie santé, Etats Unis, Amérique du Nord, Amérique, Sulfonylurées, Hypoglycémiant, Endocrinopathie, Changement médicament, Suivi thérapeutique

    Mots-clés Pascal anglais : Chemotherapy, Non insulin dependent diabetes, Treatment, Modification, Costs, Human, Health economy, United States, North America, America, Sulfonylureas, Hypoglycemic agent, Endocrinopathy, Therapeutic drug monitoring

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 96-0017235

    Code Inist : 002B02S02. Création : 01/03/1996.